Biogen Q2 2026 Earnings Report

Biogen EPS Results

• Actual EPS: N/A
• Consensus EPS: $3.20
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Biogen Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.43 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Biogen Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, July 29, 2026
• Conference Call Time: 8:30AM ET

Biogen (NASDAQ:BIIB) is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders. Biogen has also been active in the Alzheimer's field through collaborations with Eisai, bringing antibodies targeting amyloid pathology to market. In addition, Biogen has worked with partners on treatments for spinal muscular atrophy and other rare diseases, reflecting a mix of proprietary development and co-commercialization arrangements.

Biogen invests heavily in research and development, maintaining clinical-stage programs across a range of neuroscience indications and pursuing both small- and large-molecule approaches. The company operates through a combination of internal discovery, external collaborations, licensing deals and strategic acquisitions to expand its pipeline and commercial reach. Biogen is governed by an executive leadership team and a board of directors responsible for setting corporate strategy and overseeing its global operations.